Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients
- PMID: 1291405
- DOI: 10.1159/000200992
Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients
Abstract
The effect of 5 days of once-daily dosing with 20 mg p.o. and 40 mg i.v. omeprazole on pentagastrin-stimulated acid secretion was studied in 8 patients with duodenal ulcer. In addition they also received a 10-mg i.v. dose on day 6 during the oral treatment period. The antisecretory effect was measured 6-7 h after dose at a time point when maximal inhibition during the dosing interval is anticipated. The median percent inhibition of peak acid output (PAO) markedly increased from 43% on day 1 to 100% on day 5 during treatment with 20 mg p.o. The first 40-mg i.v. dose produced a median inhibition of 98% of PAO already on day 1. After 5 days of dosing, the inhibition had increased to 100%. On the other hand, a 10-mg i.v. dose could essentially maintain the degree of PAO reduction reached after 5 days of oral treatment. Plasma omeprazole concentrations increased during repeated dosing both with 20 mg p.o. and 40 mg i.v.
Similar articles
-
Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man.Gut. 1988 Jan;29(1):75-80. doi: 10.1136/gut.29.1.75. Gut. 1988. PMID: 3343017 Free PMC article.
-
[Omeprazole in peptic ulceration: acid inhibition and endoscopic healing].Zhonghua Nei Ke Za Zhi. 1989 Dec;28(12):720-1, 767. Zhonghua Nei Ke Za Zhi. 1989. PMID: 2636088 Chinese.
-
Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin.Eur J Clin Pharmacol. 1991;40(6):557-60. doi: 10.1007/BF00279969. Eur J Clin Pharmacol. 1991. PMID: 1884735
-
Effect of omeprazole on gastric acid secretion and plasma gastrin in man.Scand J Gastroenterol Suppl. 1989;166:27-32; discussion 41-2. doi: 10.3109/00365528909091240. Scand J Gastroenterol Suppl. 1989. PMID: 2690329 Review.
-
Effect of omeprazole on gastric acid secretion and plasma gastrin.J Gastroenterol Hepatol. 1989;4 Suppl 2:19-25. J Gastroenterol Hepatol. 1989. PMID: 2491358 Review.
Cited by
-
Vonoprazan: MarKed Competition for PPIs?Dig Dis Sci. 2016 Jul;61(7):1783-4. doi: 10.1007/s10620-016-4164-8. Dig Dis Sci. 2016. PMID: 27074922 Free PMC article. No abstract available.
-
Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.Eur J Drug Metab Pharmacokinet. 1998 Jan-Mar;23(1):19-26. doi: 10.1007/BF03189822. Eur J Drug Metab Pharmacokinet. 1998. PMID: 9625268
-
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.World J Gastroenterol. 2018 Apr 14;24(14):1550-1561. doi: 10.3748/wjg.v24.i14.1550. World J Gastroenterol. 2018. PMID: 29662293 Free PMC article. Clinical Trial.
-
Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.J Neurogastroenterol Motil. 2018 Jul 30;24(3):334-344. doi: 10.5056/jnm18029. J Neurogastroenterol Motil. 2018. PMID: 29739175 Free PMC article. Review.
-
Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.Aliment Pharmacol Ther. 2015 Sep;42(6):685-95. doi: 10.1111/apt.13331. Epub 2015 Jul 22. Aliment Pharmacol Ther. 2015. PMID: 26201312 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical